Objective To evaluate the clinical efficacy of mesalazine combined with triple live bacterial agent of clostridium butyricum streptococcus faecalis bacillus mesentericus for ulcerative colitis. Methods 54 patients with mild and moderate ulcerative colitis were randomly divided into two groups treatment. Group 27 patients orally took mesalazine combined with triple live bacterial agent of clostridium butyricum streptococcus faecalis bacillus mesentericus. Other 27 patients orally took mesalazine. After eight weeks of treatment, the clinical effect and changes were observed colonoscopically. Results After eight weeks of treatment, the complete remission rate in treatment group 92.5% was significantly higher than in control group 62.96% with no obvious ADR(P <0.05). Conclusion The combined therapy with mesalazine and triple live bacterial agent of clostridium butyricum streptococcus faecalis bacillus mesentericus for ulcerative colitis could significantly raise the therapeutic efficacy.
MesalazineWith triple live bacterial agent of clostridium butyricum streptococcus faecalis bacillus mesentericusUlcerative colitis